Business & Finance
Business and Finance
Business and Finance
Fri, July 24, 2009
Thu, July 23, 2009 MorphoSys AG: MorphoSys to Host Q2 2009 Conference Call on July 29, 2009
MARTINSRIED, GERMANY--(Marketwire - July 23, 2009) -
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2009 results on July 29, 2009 at 7:00 a.m. CET.
At 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EDT), the Management Board of MorphoSys AG will host a public conference call to present MorphoSys's financial results for the first six months of 2009 and provide further details on the Company's latest developments.
Dial-in numbers (listen only): Germany: +49 (0) 69 71049 1462 United Kingdom: +44 (0) 1212 604 860 USA: +1 (1) 866 347 1957
An audio replay and manuscripts of the conference will be available on [ www.morphosys.com/conferencecalls ] in the afternoon of the same day.
For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, [ gutjahr-loeser@morphosys.com ] or Mario Brkulj, Senior Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, [ brkulj@morphosys.com ]
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor Ortho Biotech Inc./Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit [ http://www.morphosys.com/ ]
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Press Release: [ http://hugin.info/130295/R/1330547/314562.pdf ]
Copyright © Hugin AS 2009. All rights reserved.
